Adjunctive chemotherapy in the form of doxirubicin has been shown to significantly improve survival times for cats with colonic adenocarcinoma, with median survival times improved from 56 to 280 days when doxorubicin treatment was used. No other evidence exists to confirm the benefits of adjuvant chemotherapy in dogs or cats. Piroxicam, a non-steroidal anti-inflammatory drug may have palliative effects for large intestinal and rectal lesions. | Adjunctive chemotherapy in the form of doxirubicin has been shown to significantly improve survival times for cats with colonic adenocarcinoma, with median survival times improved from 56 to 280 days when doxorubicin treatment was used. No other evidence exists to confirm the benefits of adjuvant chemotherapy in dogs or cats. Piroxicam, a non-steroidal anti-inflammatory drug may have palliative effects for large intestinal and rectal lesions. |